 Study Plan: Subjects will be simultaneously randomized at a ratio of 1:1:1 into one of two dosage groups or a placebo group. Subjects and clinicians will be blinded to group assignment. All subjects will receive 3 injections on the schedule shown in the schema. The protocol requires nine clinic visits and three telephone follow-up contacts. 